[{"name": "BlackRock Science and Technology Trust II", "link": "http://www.blackrock.com", "nemp": "", "ninc": "$0 mil (last 12 months)", "domain": "FINANCIAL SERVICES", "des": "The Trust has adopted restrictions and policies relating to the investment of the Trust\u2019s assets and its activities. Certain of the restrictions are fundamental policies of the Trust and may not be changed without the approval of the holders of a majority of the Trust\u2019s outstanding voting securities (which for this purpose and under the Investment Company Act means the lesser of (i)\u00a067% of the shares represented at a meeting at which more than 50% of the outstanding shares are represented or (ii)\u00a0more than 50% of the outstanding shares), including class approval by a majority of the Trust\u2019s outstanding preferred shares, if any (which for this purpose and under the Investment Company Act means the lesser of (i)\u00a067% of the preferred shares, as a single class, represented at a meeting at which more than 50% of the Trust\u2019s outstanding preferred shares are represented or (ii)\u00a0more than 50% of the outstanding preferred shares). ", "dtime": "6/26/2019 Wednesday"}, {"name": "Cambium Networks", "link": "http://www.cambiumnetworks.com", "nemp": "516", "ninc": "$0.58 mil (last 12 months)", "domain": "RADIO & TV BROADCASTING & COMMUNICATIONS EQUIPMENT", "des": "We provide wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises and government agencies. Our scalable, reliable and high performance solutions create a purpose built wireless fabric which connects people, places and things across distances ranging from two meters to more than 100 kilometers, indoors and outdoors, using licensed and unlicensed spectrum, at attractive economics. ", "dtime": "6/26/2019 Wednesday"}, {"name": "Linx S.A.", "link": "http://www.linx.com.br", "nemp": "3410", "ninc": "$15.5 mil (last 12 months)", "domain": "PREPACKAGED SOFTWARE", "des": "We are a leading cloud-based technology company in Latin America and a market leader in Brazil in terms of revenue. We are focused on developing and providing affordable, easy-to-use, reliable and seamlessly integrated software solutions to retailers in Latin America, through our software-as-a-service, or SaaS, business model. During 2018, our subscription revenue accounted for 86.8%, or R$680.8\u00a0million, of our gross operating revenue, an increase of 15.5% over 2017 in reais. During the three-month period ended March\u00a031, 2019, our subscription revenue accounted for 89.1%, or R$180.5\u00a0million, of our gross operating revenue, an increase of 11.1% over the corresponding period in 2018 in reais. With a comprehensive offering of solutions, we are an end-to-end service provider that offers business management tools, payment solutions, e-commerce and omni-channel applications through an integrated and ever-evolving platform to retailers of all sizes and capabilities. ", "dtime": "6/26/2019 Wednesday"}, {"name": "Adaptive Biotechnologies", "link": "http://www.adaptivebiotech.com", "nemp": "346", "ninc": "$-52.6 mil (last 12 months)", "domain": "BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)", "des": "We are advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature\u2019s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient\u2019s immune system and understand precisely how it detects and treats disease in that patient. ", "dtime": "6/27/2019 Thursday"}, {"name": "BridgeBio Pharma", "link": "http://www.bridgebio.com", "nemp": "152", "ninc": "$-167.9 mil (last 12 months)", "domain": "PHARMACEUTICAL PREPARATIONS", "des": "We are a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. We founded BridgeBio in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Our pipeline of over 15 development programs includes product candidates ranging from early discovery to late-stage development.", "dtime": "6/27/2019 Thursday"}, {"name": "Change Healthcare", "link": "https://www.changehealthcare.com", "nemp": "14000", "ninc": "$-51.9 mil (last 12 months)", "domain": "COMPUTER PROCESSING & DATA PREPARATION", "des": "We are a leading independent healthcare technology platform that provides data and analytics-driven solutions to improve clinical, financial and patient engagement outcomes in the U.S. healthcare system. We offer a comprehensive suite of software, analytics, technology-enabled services and network solutions that drive improved results in the complex workflows of healthcare system payers and providers. Our solutions are designed to improve clinical decision making, simplify billing, collection and payment processes and enable a better patient experience. ", "dtime": "6/27/2019 Thursday"}, {"name": "Morphic Holding", "link": "http://www.morphictx.com", "nemp": "65", "ninc": "$-23.9 mil (last 12 months)", "domain": "PHARMACEUTICAL PREPARATIONS", "des": "We are a biopharmaceutical company applying our proprietary insights into integrins to discover and develop a pipeline of potentially first-in-class oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. To date, no oral small-molecule integrin therapies have been approved by the U.S. Food and Drug Administration, or FDA. Despite significant unsuccessful efforts, we believe tremendous untapped potential remains for us to develop oral integrin therapies. ", "dtime": "6/27/2019 Thursday"}, {"name": "Priam Properties", "link": "http://www.priamproperties.com", "nemp": "10", "ninc": "$-741 mil (last 12 months)", "domain": "REAL ESTATE INVESTMENT TRUSTS", "des": "We are a newly formed, self-administered and self-managed real estate investment company focused on acquiring, improving, owning and managing multi-tenant office properties in high-growth urban nodes in the Midwest and Southeast United States within target markets, which we define as MSAs, other than the major markets, that have populations of at least one million people. We intend to elect to be taxed and to operate in a manner that will allow us to qualify as a REIT for federal income tax purposes commencing with our short taxable year ending December\u00a031, 2019. ", "dtime": "6/27/2019 Thursday"}, {"name": "Karuna Therapeutics", "link": "http://www.karunatx.com", "nemp": "16", "ninc": "$-27.1 mil (last 12 months)", "domain": "PHARMACEUTICAL PREPARATIONS", "des": "We are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. Our pipeline is built on the broad therapeutic potential of our lead product candidate, KarXT, an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues. KarXT is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. We are currently conducting a Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia and expect topline results in late 2019.", "dtime": "6/28/2019 Friday"}, {"name": "Pivotal Investment Corporation II", "link": "", "nemp": "0", "ninc": "$0 mil (last 12 months)", "domain": "BLANK CHECKS", "des": "We believe that acquiring a leading, high- growth participant will provide a public currency to fund consolidation and fuel growth. Segments we might explore include, but are not limited to, logistics technology and \u201clast mile\u201d delivery services, business technology services, on-line cyber security and off-line physical security services, media and entertainment services and franchise businesses. ", "dtime": "6/28/2019 Friday"}, {"name": "TheRealReal", "link": "http://www.therealreal.com", "nemp": "1700", "ninc": "$-96.0 mil (last 12 months)", "domain": "MISCELLANEOUS RETAIL", "des": "The RealReal is the world\u2019s largest online marketplace for authenticated, consigned luxury goods. We are revolutionizing luxury resale by providing an end-to-end service that unlocks supply from consignors and creates a trusted, curated online marketplace for buyers globally. Over the past eight years, we have cultivated a loyal and engaged consignor and buyer base through continuous investment in our technology platform, logistics infrastructure and people. ", "dtime": "6/28/2019 Friday"}]